Literature DB >> 11751884

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.

Takeshi Ueda1, Nicholas Bruchovsky, Marianne D Sadar.   

Abstract

The androgen receptor (AR) is a ligand-activated transcription factor that mediates the biological responses of androgens. However, non-androgenic pathways have also been shown to activate the AR. The mechanism of cross-talk between the interleukin-6 (IL-6) and AR signal transduction pathways was investigated in LNCaP human prostate cancer cells. IL-6 induced several androgen-response element-driven reporters that are dependent upon the AR, increased the phosphorylation of mitogen-activated protein kinase (MAPK), and activated the AR N-terminal domain (NTD). Inhibitors to MAPK and JAK decreased the IL-6-induced phosphorylation of MAPK and activation of the AR NTD. Immunoprecipitation and transactivation studies showed a direct interaction between amino acids 234-558 of the AR NTD and STAT3 following IL-6 treatment of LNCaP cells. These results demonstrate that activation of the human AR NTD by IL-6 was mediated through MAPK and STAT3 signal transduction pathways in LNCaP prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751884     DOI: 10.1074/jbc.M108255200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  117 in total

Review 1.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 2.  Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.

Authors:  Marianne D Sadar
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

Review 3.  Role of desumoylation in the development of prostate cancer.

Authors:  Jinke Cheng; Tasneem Bawa; Peng Lee; Limin Gong; Edward T H Yeh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  Androgen receptor decoy molecules block the growth of prostate cancer.

Authors:  Steven N Quayle; Nasrin R Mawji; Jun Wang; Marianne D Sadar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

Review 5.  Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

Authors:  Marianne D Sadar
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

6.  Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.

Authors:  Na Shang; Hao Wang; Thomas Bank; Aldeb Perera; Cara Joyce; Gina Kuffel; Michael J Zilliox; Scott J Cotler; Xianzhong Ding; Asha Dhanarajan; Peter Breslin; Wei Qiu
Journal:  Hepatology       Date:  2019-06-22       Impact factor: 17.425

7.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

Review 8.  The role of estrogens and estrogen receptors in normal prostate growth and disease.

Authors:  Gail S Prins; Kenneth S Korach
Journal:  Steroids       Date:  2007-11-12       Impact factor: 2.668

9.  AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization.

Authors:  Jeremy O Jones; W Frank An; Marc I Diamond
Journal:  ACS Chem Biol       Date:  2009-03-20       Impact factor: 5.100

10.  Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Authors:  Belen Elguero; Geraldine Gueron; Jimena Giudice; Martin A Toscani; Paola De Luca; Florencia Zalazar; Federico Coluccio-Leskow; Roberto Meiss; Nora Navone; Adriana De Siervi; Elba Vazquez
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.